AIP
MRNA icon

ARS Investment Partners’s Moderna MRNA Stock Holding History

ARS Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,887
Closed -$2.67M – 167
2023
Q4 		$2.67M Sell
26,887
-43,363
-62% -$3.65M 0.3% 53
2023
Q3 		$7.26M Sell
70,250
-1,406
-2% -$157K 0.9% 34
2023
Q2 		$8.71M Sell
71,656
-4,127
-5% -$551K 1.02% 31
2023
Q1 		$11.6M Buy
75,783
+537
+0.7% +$88.6K 1.4% 25
2022
Q4 		$13.5M Buy
75,246
+71,736
+2,044% +$11.7M 1.8% 20
2022
Q3 		$415K Buy
+3,510
New +$533K 0.06% 108
2021
Q1 		– Sell
-3,730
Closed -$390K – 144
2020
Q4 		$390K Buy
3,730
+530
+17% +$53.6K 0.05% 90
2020
Q3 		$226K Buy
+3,200
New +$223K 0.04% 94

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ARS Investment Partners's MRNA Position: Q1 2024 in Review

ARS Investment Partners sold out of Moderna (MRNA) in Q1 2024, closing a stake of 26,887 shares — an estimated $2.67M sold.

ARS Investment Partners first reported a position in MRNA in Q3 2020 and held it in 8 quarters. The position peaked at $13.5M in Q4 2022. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • ARS Investment Partners reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • ARS Investment Partners sold 26,887 Moderna shares in Q1 2024, an estimated $2.67M.
  • ARS Investment Partners first reported a position in Moderna in Q3 2020 and held it in 8 quarters.
  • ARS Investment Partners's Moderna position peaked at $13.5M in Q4 2022.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on ARS Investment Partners's 13F filing for Q1 2024, filed 2 May 2024.